Bristol-Myers Squibb Symposium
Noyes 153 (J. Holmes Sturdivant Lecture Hall)
Understanding Palladium Ligation, Activation and Turnover in the Development of Novel Approaches to a Complex Clinical Candidate
Martin D. Eastgate,
Dr., Ph.D., Director,
Early-Phase Chemical Development,
Bristol-Myers Squibb,
This seminar will describe the strategy employed to develop 3 new synthetic approaches to a complex clinical candidate. In preparing the target molecule, novel chemical transformations were discovered, along with a detailed understanding of several palladium mediated transformations; these studies elucidated the importance of palladium reduction, ligand oxidation and catalyst turnover. These discoveries will be described, along with an overview of the chemical exploration of this complex small molecule.
For more information, please contact Lynne Martinez by phone at 626-395-4004 or by email at [email protected].
Event Series
Bristol Myers-Squibb Symposium